Menü
sharewise sharewise
Einloggen
Registrieren
Einloggen
Registrieren
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Erstellt von Brookline Capital Management 

Oncternal Therapeutics Inc. diskutieren

Oncternal Therapeutics Inc.

WKN: A2PL3P / Symbol: ONCT / Name: Oncternal Therapeutics / Aktie / Small Cap /

0,32 €
4,71 %

4 19
4
19

Oncternal Therapeutics, Inc. (NASDAQ: ONCT) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for ONCT provided by MarketBeat

StockNews.com 
0
Melden Teilen
17.12.23 Sell -16,35 %

Oncternal Therapeutics, Inc. (NASDAQ: ONCT) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for ONCT provided by MarketBeat

StockNews.com 
0
Melden Teilen
25.12.23 Sell -41,48 %
Einschätzung Buy
Rendite (%) -41,48 %
Kursziel 1,81
Veränderung
Endet am 27.12.24

Oncternal Therapeutics, Inc. (NASDAQ: ONCT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $2.00 price target on the stock.
Ratings data for ONCT provided by MarketBeat

HC Wainwright 
0
Melden Teilen
27.12.23

Oncternal Therapeutics, Inc. (NASDAQ: ONCT) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for ONCT provided by MarketBeat

StockNews.com 
0
Melden Teilen
18.01.24 Sell -

Oncternal Therapeutics, Inc. (NASDAQ: ONCT) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for ONCT provided by MarketBeat

StockNews.com 
0
Melden Teilen
26.01.24 Sell -
Einschätzung Buy
Rendite (%) -
Kursziel 27,72
Veränderung
Endet am 29.01.25

Oncternal Therapeutics, Inc. (NASDAQ: ONCT) had its price target raised by analysts at HC Wainwright to $30.00. They now have a "buy" rating on the stock.
Ratings data for ONCT provided by MarketBeat

HC Wainwright 
0
Melden Teilen
29.01.24
Einschätzung Buy
Rendite (%) -
Kursziel 26,28
Veränderung
Endet am 15.04.25

Oncternal Therapeutics, Inc. (NASDAQ: ONCT) had its price target lowered by analysts at HC Wainwright from $30.00 to $28.00. They now have a "buy" rating on the stock.
Ratings data for ONCT provided by MarketBeat

HC Wainwright 
0
Melden Teilen
15.04.24
Noch kein Mitglied? Jetzt kostenlos registrieren!

Neueste Beiträge

DA_Davidson in eXp World Holdings diskutieren
eXp World Holdings, Inc. (NASDAQ: EXPI) had its "underpe...
02.05.24
Needham___Company_LL in Geron Corp. diskutieren
Geron Co. (NASDAQ: GERN) had its "buy" rating re-affirme...
02.05.24
Barrington_Research in Discuss Barrett Business Services Inc.
Barrett Business Services, Inc. (NASDAQ: BBSI) had its "...
02.05.24
HC_Wainwright in G1 Therapeutics diskutieren
G1 Therapeutics, Inc. (NASDAQ: GTHX) had its "buy" ratin...
02.05.24
B__Riley in Formfactor Inc. diskutieren
FormFactor, Inc. (NASDAQ: FORM) had its price target rais...
02.05.24
B__Riley in Extreme Networks diskutieren
Extreme Networks, Inc. (NASDAQ: EXTR) had its price targe...
02.05.24
HC_Wainwright in Corcept Therapeutics Inc. diskutieren
Corcept Therapeutics Incorporated (NASDAQ: CORT) had its ...
02.05.24
HC_Wainwright in TG Therapeutics Inc. diskutieren
TG Therapeutics, Inc. (NASDAQ: TGTX) had its price target...
02.05.24
Mehr anzeigen